Medication
| Metric | Compounded semaglutide |
|---|---|
| FDA-approved? | No, compounded preparations are not FDA-approved |
| Typical route | Often weekly injection, depending on prescription |
| Common side effects | Nausea, constipation, diarrhea, appetite changes |
| Eligibility | Requires clinician review |
Fact-checked by Dr. J. Adam, MD on . See our fact-checking policy.
Compounded semaglutide is prepared by licensed compounding pharmacies (503A or 503B) for individual patients. Not FDA-approved as a finished drug. April 2026 FDA guidance tightened advertising and prescribing rules for compounded GLP-1 products. Pricing in patient-direct telehealth typically ranges $145–$215/month.
| Topic | What patients should verify |
|---|---|
| Approval status | Whether the product is FDA-approved brand-name medication or a compounded version. |
| Dosing | Starting dose, titration schedule, maintenance dose, and instructions from the prescriber. |
| Safety | Contraindications, side effects, drug interactions, and when to contact a clinician. |
| Cost | Monthly price, dose changes, insurance coverage, shipping, labs, and cancellation terms. |
| Generic name | semaglutide |
| Brand manufacturer | 503A and 503B compounding pharmacies |
| FDA indication | Compounded — not FDA-approved as a finished drug |
| FDA approval year | N/A (compounded) |
| Form | Subcutaneous injection (multi-dose vial + syringe) |
| Schedule | Once weekly |
| List price (cash) | $145–$165/mo |
For drug-class comparisons, see our medication-comparison hub:
Coverage varies significantly by carrier and employer plan. See our insurance hub for plan-specific guidance:
Compounded semaglutide is reviewed here as non-FDA-approved compounded GLP-1 option prescribed after clinician review. The practical decision is not simply whether the medication is popular; it is whether the medication pathway, dose schedule, safety profile, cost, insurance position, and follow-up model fit the patient’s clinical situation. This section expands the page into a more complete decision guide for readers comparing Compounded semaglutide with other GLP-1 options, compounded alternatives, and telehealth providers.
Because this is a compounded medication page, the key issue is not brand-name list price but whether the prescriber documents clinical need, the dispensing pharmacy is licensed for the patient’s state, and the final formulation is clear. A patient should verify the current label, indication, eligibility criteria, contraindications, and coverage requirements with a licensed clinician. This page is for education and comparison only; it is not a prescription, diagnosis, or recommendation to start, stop, or change treatment.
Medication: Compounded semaglutide
Generic or active ingredient: semaglutide prepared by a licensed compounding pharmacy when appropriate
Primary manufacturer/source: licensed compounding pharmacy
Typical pathway: clinician review before treatment.
Compare Compounded semaglutide by indication, dosing frequency, expected cost, insurance coverage, side-effect tolerance, pharmacy source, and whether the patient needs brand-name medication or is considering a compounded alternative.
Compounded dosing instructions vary by concentration, vial size, pharmacy, and prescription. Patients should never convert units without written instructions from the prescriber or pharmacy. Dose escalation is usually gradual because gastrointestinal side effects are more common during initiation and dose increases. Patients should ask what dose they are starting, when the next increase is considered, what side effects should delay titration, and how to contact the care team if nausea, vomiting, constipation, dehydration, or appetite suppression becomes difficult to manage.
| Decision point | What to verify | Why it matters |
|---|---|---|
| Starting dose | The exact dose, unit instructions, injection frequency, and first refill date. | Clear instructions reduce administration errors and help patients plan side-effect management. |
| Titration plan | When dose increases are expected and what symptoms should pause escalation. | GLP-1 treatment is usually adjusted based on tolerability rather than speed alone. |
| Maintenance dose | Whether the target dose is fixed, flexible, or based on response and side effects. | Cost and clinical response often change once the patient reaches maintenance dosing. |
| Missed dose rules | What to do if an injection or tablet is missed, delayed, or vomited after administration. | Patients should not double doses or improvise without instructions. |
Clinical expectations should be framed as ranges, not guarantees. Response varies by medication, adherence, nutrition, physical activity, baseline weight, comorbidities, dose, and duration of therapy. Many patients notice appetite changes before visible weight changes. Early progress may include smaller portions, fewer cravings, and improved control around meals. Weight loss, when it occurs, is usually gradual and should be interpreted over months rather than days. The most useful clinical question is whether the patient is tolerating therapy, maintaining hydration and protein intake, preserving muscle, and improving metabolic risk markers where relevant.
For comparison research, avoid pages or providers that promise a specific number of pounds lost. A medically responsible GLP-1 page should distinguish clinical-trial averages from individual results, explain that placebo-adjusted outcomes are not personal guarantees, and remind patients that nutrition, resistance training, sleep, and follow-up care influence outcomes.
The most common GLP-1-related side effects are gastrointestinal. Nausea, constipation, diarrhea, reflux, burping, early fullness, and reduced appetite are commonly discussed across the drug class. Some patients have mild symptoms that improve with slower meals and hydration. Others need dose holds, anti-nausea support, constipation management, or a change in treatment plan. Severe or persistent symptoms should be reviewed by a clinician.
| Treatment phase | Common patient questions | Useful clinical follow-up |
|---|---|---|
| First month | Is nausea normal? How much appetite suppression is too much? | Review hydration, meal size, protein intake, constipation prevention, and red-flag symptoms. |
| Dose increase | Should I increase if I still have side effects? | Ask whether to hold the current dose longer rather than escalating automatically. |
| Maintenance | What if weight loss slows? | Evaluate adherence, nutrition, muscle preservation, sleep, dose, and whether the plateau is expected. |
| Stopping or pausing | Will appetite return? | Discuss maintenance strategy, behavioral support, and whether a taper or alternative plan is appropriate. |
Compounded semaglutide belongs to the broader GLP-1 medication category and should be evaluated carefully in patients with relevant personal or family history, pregnancy plans, gallbladder disease, pancreatitis history, severe gastrointestinal disease, kidney concerns related to dehydration, or medication interactions. The exact contraindications and warnings depend on the specific product and label. Patients should review the official prescribing information with their clinician and disclose all medications and supplements.
Cost should be compared at the annual level, not only by the first advertised month. For Compounded semaglutide, patients should ask whether the listed price includes medication, consultation, labs, supplies, shipping, dose increases, and follow-up. Insurance coverage often depends on diagnosis, employer plan design, prior authorization rules, step therapy, and whether the medication is being used for an FDA-approved indication. Cash-pay telehealth options may be easier to start but may not reduce long-term cost if follow-up, labs, or dose changes are separate.
| Cost factor | Question to ask |
|---|---|
| Medication price | Is the price introductory, monthly, annualized, dose-based, or flat-rate? |
| Clinical care | Are provider review, follow-ups, and messaging included? |
| Insurance | Does the program bill insurance, help with prior authorization, or operate cash-pay only? |
| Pharmacy/shipping | Are shipping, supplies, cold-chain packaging, and replacement rules clearly disclosed? |
Patients comparing Compounded semaglutide with semaglutide, tirzepatide, liraglutide, dulaglutide, or compounded options should use a consistent framework: FDA status, indication, route, dosing frequency, clinical evidence, expected tolerability, contraindications, cost, and provider support. A lower sticker price is not automatically better if the patient receives unclear dosing instructions or limited follow-up. A brand-name pathway is not automatically better if the medication is not covered and the out-of-pocket cost is unaffordable.
For patients using GLP Agonists as a comparison resource, the next best step is usually to compare Compounded semaglutide against the closest alternative: semaglutide versus tirzepatide for weight-management decisions, Ozempic versus Wegovy for semaglutide brand positioning, Mounjaro versus Zepbound for tirzepatide brand positioning, or compounded versus brand-name medication for cash-pay access decisions.
Compounded Semaglutide is the brand name for semaglutide, manufactured by 503A and 503B compounding pharmacies. Compounded semaglutide is prepared by licensed compounding pharmacies (503A or 503B) for individual patients. Not FDA-approved as a finished drug. April 2026 FDA guidance tightened advertising and pre
Compounded Semaglutide list price is approximately $145–$165/mo. Insurance may cover it with prior authorization for FDA-approved indications.
Not FDA-approved (compounded). Indication: Compounded — not FDA-approved as a finished drug.
Doses available: Custom titration: typical 0.25 mg → 2.4 mg weekly. Schedule: Once weekly. Always follow your prescribing clinician's titration plan.
See our medication comparisons hub for head-to-head pages on Wegovy vs Zepbound, Ozempic vs Wegovy, and semaglutide vs tirzepatide.
Note: This page is an editorial overview, not medical advice. Always consult a licensed clinician about whether Compounded Semaglutide is appropriate for you.